

# Bruno C Medeiros

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/944110/publications.pdf>

Version: 2024-02-01

129  
papers

8,501  
citations

136885

32  
h-index

46771

89  
g-index

132  
all docs

132  
docs citations

132  
times ranked

9900  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. <i>New England Journal of Medicine</i> , 2017, 377, 454-464.  | 13.9 | 1,628     |
| 2  | Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2017, 130, 722-731.  | 0.6  | 1,173     |
| 3  | Functional genomic landscape of acute myeloid leukaemia. <i>Nature</i> , 2018, 562, 526-531.   | 13.7 | 907       |
| 4  | CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 2684-2692.  | 0.8  | 682       |
| 5  | Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. <i>Nature Medicine</i> , 2015, 21, 178-184.  | 15.2 | 459       |
| 6  | Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3641-3649.   | 0.8  | 340       |
| 7  | Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States. <i>Annals of Hematology</i> , 2015, 94, 1127-1138.  | 0.8  | 219       |
| 8  | Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. <i>Blood</i> , 2014, 124, 385-392.  | 0.6  | 195       |
| 9  | Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. <i>Cell Reports</i> , 2017, 18, 3204-3218.  | 2.9  | 187       |
| 10 | Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. <i>Blood</i> , 2010, 116, 2224-2228.   | 0.6  | 180       |
| 11 | Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. <i>Blood</i> , 2016, 127, 1017-1023.  | 0.6  | 179       |
| 12 | Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. <i>Journal of Clinical Oncology</i> , 2016, 34, 7000-7000.   | 0.8  | 130       |
| 13 | Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020, 135, 371-380.   | 0.6  | 127       |
| 14 | Development and Validation of a Novel Acute Myeloid Leukemia Composite Model to Estimate Risks of Mortality. <i>JAMA Oncology</i> , 2017, 3, 1675.   | 3.4  | 125       |
| 15 | The Multi-Kinase inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (mut): An International Prospective Randomized (rand) Controlled Double-Blind Trial (CALGB 12600/DAVID/ALLIANCE-3). <i>Blood</i> , 2015, 126, 6-6. | 0.6  | 104       |
| 16 | Mass Cytometric Functional Profiling of Acute Myeloid Leukemia Defines Cell-Cycle and Immunophenotypic Properties That Correlate with Known Responses to Therapy. <i>Cancer Discovery</i> , 2015, 5, 988-1003.   | 7.7  | 93        |
| 17 | Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E7554-E7563.  | 3.3  | 86        |
| 18 | NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1357-1370.  | 2.3  | 82        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing. <i>Blood Reviews</i> , 2018, 32, 289-299.   | 2.8 | 67        |
| 20 | Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. <i>Haematologica</i> , 2012, 97, 1401-1404.   | 1.7 | 64        |
| 21 | Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. <i>Blood Advances</i> , 2019, 3, 508-518.   | 2.5 | 62        |
| 22 | Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. <i>Haematologica</i> , 2013, 98, 591-596.  | 1.7 | 58        |
| 23 | Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial. <i>Blood</i> , 2015, 126, 323-323.  | 0.6 | 57        |
| 24 | Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis. <i>Cancer</i> , 2015, 121, 2004-2012.   | 2.0 | 56        |
| 25 | Plasma Microbial Cell-free DNA Next-generation Sequencing in the Diagnosis and Management of Febrile Neutropenia. <i>Clinical Infectious Diseases</i> , 2022, 74, 1659-1668.  | 2.9 | 56        |
| 26 | Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. <i>Blood</i> , 2019, 134, 867-879.  | 0.6 | 55        |
| 27 | Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, 803-811.  | 2.0 | 51        |
| 28 | Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021, 35, 2539-2551.  | 3.3 | 51        |
| 29 | Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. <i>Leukemia</i> , 2022, 36, 90-99.  | 3.3 | 42        |
| 30 | SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2016, 128, 901-901. | 0.6 | 42        |
| 31 | Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin. <i>PLoS ONE</i> , 2019, 14, e0219547.   | 1.1 | 38        |
| 32 | Disparities in early death and survival in children, adolescents, and young adults with acute promyelocytic leukemia in California. <i>Cancer</i> , 2015, 121, 3990-3997.   | 2.0 | 34        |
| 33 | Interpretation of clinical endpoints in trials of acute myeloid leukemia. <i>Leukemia Research</i> , 2018, 68, 32-39.   | 0.4 | 34        |
| 34 | Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020, 4, 4945-4954.  | 2.5 | 34        |
| 35 | Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.  | 2.0 | 33        |
| 36 | Effects of Education and Income on Treatment and Outcome in Patients With Acute Myeloid Leukemia in a Tax-Supported Health Care System: A National Population-Based Cohort Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3678-3687.  | 0.8 | 30        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). <i>Leukemia Research</i> , 2010, 34, 594-597.  | 0.4 | 29        |
| 38 | Unsuccessful diagnostic cytogenetic analysis is a poor prognostic feature in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2014, 164, 245-250.   | 1.2 | 27        |
| 39 | Identification of Doxorubicin as an Inhibitor of the IRE1 $\alpha$ -XBP1 Axis of the Unfolded Protein Response. <i>Scientific Reports</i> , 2016, 6, 33353.   | 1.6 | 27        |
| 40 | Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 387-400.   | 0.6 | 26        |
| 41 | Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, 331-335.   | 1.7 | 24        |
| 42 | Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). <i>Leukemia Research</i> , 2018, 67, 17-20.                                    | 0.4 | 23        |
| 43 | Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2016, 57, 609-615.   | 0.6 | 21        |
| 44 | Impact of Allogeneic Stem Cell Transplantation in First Complete Remission in Acute Myeloid Leukemia: A National Population-Based Cohort Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 314-323.                                   | 2.0 | 21        |
| 45 | Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience. <i>Leukemia and Lymphoma</i> , 2020, 61, 2700-2707.   | 0.6 | 21        |
| 46 | Predictors of early death and survival among children, adolescents and young adults with acute myeloid leukaemia in California, 1988-2011: a population-based study. <i>British Journal of Haematology</i> , 2016, 173, 292-302.                          | 1.2 | 20        |
| 47 | Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 453-453.   | 0.6 | 20        |
| 48 | Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database. <i>Advances in Therapy</i> , 2019, 36, 1922-1935. | 1.3 | 19        |
| 49 | Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial. <i>British Journal of Haematology</i> , 2019, 185, 595-598.  | 1.2 | 19        |
| 50 | Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population-based case-control study. <i>British Journal of Haematology</i> , 2018, 181, 205-214.  | 1.2 | 18        |
| 51 | Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, 101-106.                       | 1.7 | 18        |
| 52 | Is there a standard of care for relapsed AML?. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 384-386.   | 0.7 | 18        |
| 53 | A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit. <i>Blood</i> , 2016, 128, 100-100.                                 | 0.6 | 18        |
| 54 | Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients. <i>Oncotarget</i> , 2016, 7, 72044-72056.  | 0.8 | 18        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 55 | Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. <i>Leukemia Research</i> , 2019, 85, 106197.   | 0.4  | 16        |
| 56 | Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2020, 26, 849-859.   | 0.5  | 16        |
| 57 | Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial. <i>Blood</i> , 2016, 128, 906-906. | 0.6  | 16        |
| 58 | Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial. <i>Blood</i> , 2016, 128, 902-902.  | 0.6  | 15        |
| 59 | Localized skin-limited blastic plasmacytoid dendritic cell neoplasm: A subset with possible durable remission without transplantation. <i>JAAD Case Reports</i> , 2017, 3, 310-315.   | 0.4  | 14        |
| 60 | Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2012, 87, 45-50.   | 2.0  | 13        |
| 61 | Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species. <i>Clinical Cancer Research</i> , 2016, 22, 1978-1988.   | 3.2  | 13        |
| 62 | Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to reinduction chemotherapy. <i>American Journal of Hematology</i> , 2020, 95, 245-250.  | 2.0  | 13        |
| 63 | Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome. <i>Blood Advances</i> , 2022, 6, 1152-1161.  | 2.5  | 13        |
| 64 | Novel Therapeutics in Acute Myeloid Leukemia. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 495-503.   | 1.8  | 12        |
| 65 | Complete remission of primary plasma cell leukemia with bortezomib, doxorubicin, and dexamethasone: a case report. <i>Cases Journal</i> , 2009, 2, 121.   | 0.4  | 11        |
| 66 | Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2014, 38, 1441-1445.   | 0.4  | 11        |
| 67 | Chemotherapy options for previously untreated acute myeloid leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2149-2162.   | 0.9  | 11        |
| 68 | Treatment patterns in patients with acute myeloid leukemia in the United States: a cross-sectional, real-world survey. <i>Current Medical Research and Opinion</i> , 2019, 35, 927-935.   | 0.9  | 11        |
| 69 | BCL-2 Inhibition As a Synthetic Lethal Approach To Target Isocitrate Dehydrogenase Mutations In Acute Myeloid Leukemia Stem Cells. <i>Blood</i> , 2013, 122, 885-885.   | 0.6  | 11        |
| 70 | Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype. <i>Haematologica</i> , 2011, 96, 631-632.  | 1.7  | 10        |
| 71 | Cytarabine Dose for Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2011, 364, 2166-2169.  | 13.9 | 10        |
| 72 | Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia. <i>Leukemia Research</i> , 2014, 38, 564-568.   | 0.4  | 10        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function. <i>Cancer Research</i> , 2017, 77, 4258-4267.   | 0.4 | 10        |
| 74 | Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2â€“mutated blastic plasmacytoid dendritic cell neoplasm. <i>Human Pathology</i> , 2015, 46, 322-326.  | 1.1 | 8         |
| 75 | Real-World Treatment Patterns and Comparative Effectiveness Among a Population of Elderly Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 835-835.   | 0.6 | 8         |
| 76 | The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study. <i>Blood</i> , 2010, 116, 658-658.  | 0.6 | 7         |
| 77 | Impact of residual normal metaphases in core binding factor acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 2420-2423.  | 2.0 | 6         |
| 78 | Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.. <i>Blood</i> , 2009, 114, 1015-1015.  | 0.6 | 6         |
| 79 | Impact of Comorbidities at Diagnosis of Acute Myeloid Leukemia on One-Year Mortality. <i>Blood</i> , 2015, 126, 532-532.   | 0.6 | 6         |
| 80 | Associations between cohabitation status, treatment, and outcome in AML patients: a national population-based study. <i>Blood</i> , 2018, 131, 2730-2733.  | 0.6 | 5         |
| 81 | Addressing the room for improvement in management of acute promyelocytic leukemia. <i>European Journal of Haematology</i> , 2019, 102, 479-485.  | 1.1 | 5         |
| 82 | Functional characterization of two rare BCRâ€“FGFR1<sup>+</sup> leukemias. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a004838.  | 0.5 | 5         |
| 83 | Update of a Phase I/II Trial of 5-Azacytidine Prior to Gemtuzumab Ozogamicin (GO) for Patients with Relapsed Acute Myeloid Leukemia with Correlative Biomarker Studies. <i>Blood</i> , 2010, 116, 3286-3286.   | 0.6 | 5         |
| 84 | Feasibility of Allogeneic Hematopoietic Cell Transplantation Among High-Risk AML Patients in First Complete Remission: Results of the Transplant Objective from the SWOG (S1203) Randomized Phase III Study of Induction Therapy Using Standard 7+3 Therapy or Idarubicin with High-Dose Cytarabine (IA) Versus IA Plus Vorinostat. <i>Blood</i> , 2016, 128, 1166-1166. | 0.6 | 5         |
| 85 | Plasma cell leukemia: concepts and management. <i>Expert Review of Hematology</i> , 2010, 3, 543-549.  | 1.0 | 4         |
| 86 | <p>Longer distance to specialized treatment centers does not adversely affect treatment intensity or outcomes in adult acute myeloid leukemia patients. A Danish national population-based cohort study</p>. <i>Clinical Epidemiology</i> , 2019, Volume 11, 769-780.  | 1.5 | 4         |
| 87 | MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study. <i>Blood</i> , 2013, 122, 1443-1443.   | 0.6 | 4         |
| 88 | Chemotherapy dose in obese AML patients: To cap or not to cap?. <i>Leukemia Research</i> , 2015, 39, 30-32.  | 0.4 | 3         |
| 89 | A phase 1, openâ€“label, doseâ€“escalation study of pralatrexate inÂcombination with bortezomib in patients with relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2016, 173, 253-259.   | 1.2 | 3         |
| 90 | Long non-coding RNAs: another brick in the wall of normal karyotype acute myeloid leukemia?. <i>Haematologica</i> , 2017, 102, 1301-1303.  | 1.7 | 3         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Increase in Chemotherapy Use and Associated Survival Benefit Among Medicare-Aged Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 3591-3591.  | 0.6 | 3         |
| 92  | The Impact of Distance to Treatment Center on the Outcome of AML. <i>Blood</i> , 2010, 116, 4742-4742.   | 0.6 | 3         |
| 93  | Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2017, 35, 7036-7036.                                  | 0.8 | 3         |
| 94  | Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort study. <i>Leukemia and Lymphoma</i> , 2022, 63, 2290-2300.   | 0.6 | 3         |
| 95  | Non-zero-sum game of transfusions: EOL in leukemia. <i>Blood</i> , 2018, 132, 676-678.   | 0.6 | 2         |
| 96  | The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900). <i>Leukemia Research</i> , 2019, 78, 29-33.  | 0.4 | 2         |
| 97  | Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study. <i>Blood</i> , 2018, 132, 207-207. | 0.6 | 2         |
| 98  | Correlation between mutation clearance and clinical response in elderly patients with acute myeloid leukemia (AML) treated with azacitidine and pracinostat.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7034-7034.   | 0.8 | 2         |
| 99  | Epidemiology of invasive fungal diseases in adults with newly diagnosed acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, , 1-7.  | 0.6 | 2         |
| 100 | Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile. <i>Bone Marrow Transplantation</i> , 2015, 50, 1004-1006.   | 1.3 | 1         |
| 101 | A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. <i>International Journal of Hematology</i> , 2018, 108, 267-273.                        | 0.7 | 1         |
| 102 | Influence of Residual Normal Metaphases In Patients with Monosomal Karyotype.. <i>Blood</i> , 2010, 116, 1671-1671.  | 0.6 | 1         |
| 103 | Predictors of Early Death and Survival Among Children, Adolescents and Young Adults with Acute Myeloid Leukemia in California, 1988-2011: A Population-Based Study. <i>Blood</i> , 2015, 126, 1323-1323.   | 0.6 | 1         |
| 104 | High Risk of Early Mortality in Adult Patients with Acquired Hemophagocytic Lymphohistiocytosis.. <i>Blood</i> , 2009, 114, 1359-1359.   | 0.6 | 1         |
| 105 | Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm. <i>Blood</i> , 2012, 120, 3594-3594.                                  | 0.6 | 1         |
| 106 | Mcl-1 Dependence Predicts Response To Vorinostat and Gemtuzumab Ozogamicin In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 1305-1305.   | 0.6 | 1         |
| 107 | Augmentation of the Acute Myeloid Leukemia-Composite Model (AML-CM) with Performance Status and Secondary Leukemia. <i>Blood</i> , 2018, 132, 3992-3992.   | 0.6 | 1         |
| 108 | The Relationship between Age and Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in a Cohort of Older Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 3588-3588.   | 0.6 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Unveiling the complexity of CK+ AML. <i>Blood</i> , 2012, 119, 1958-1959.   | 0.6 | 0         |
| 110 | Facts about FCE (Fludarabine, Cytarabine, Etoposide) in Acute Myeloid Leukemia. <i>Acta Haematologica</i> , 2014, 131, 200-201.   | 0.7 | 0         |
| 111 | Polypharmacy in AML: The tip of the Iceberg. <i>Leukemia Research</i> , 2014, 38, 1378-1379.  | 0.4 | 0         |
| 112 | Why do subjects on clinical trials discontinue therapy? Do we really know?. <i>Leukemia Research</i> , 2016, 51, 19-21.   | 0.4 | 0         |
| 113 | Chemotherapy based combinations in AML: Time to take a step back?. <i>Leukemia Research</i> , 2018, 73, 39-40.  | 0.4 | 0         |
| 114 | 1735. Epidemiology of Invasive Fungal Infections During Induction Chemotherapy in Adults With Newly Diagnosed Acute Myeloid Leukemia Without Antifungal Prophylaxis: A Retrospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S635-S636.      | 0.4 | 0         |
| 115 | 2532. Identifying Educational Needs and Improving Provider Knowledge Regarding the Management of Febrile Neutropenia. <i>Open Forum Infectious Diseases</i> , 2019, 6, S880-S880.   | 0.4 | 0         |
| 116 | Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19005-e19005.  | 0.8 | 0         |
| 117 | A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2010, 116, 3288-3288.   | 0.6 | 0         |
| 118 | Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Statusâ€‘Based Treatment Stratification. <i>Blood</i> , 2010, 116, 3313-3313.   | 0.6 | 0         |
| 119 | Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm,. <i>Blood</i> , 2011, 118, 3617-3617. | 0.6 | 0         |
| 120 | Application of Mass Cytometry to Measure Proliferation During Normal and Malignant Hematopoietic Differentiation. <i>Blood</i> , 2011, 118, 4782-4782.  | 0.6 | 0         |
| 121 | Qualitative analysis of practicing oncologistsâ€™ attitudes and experiences regarding HIT-facilitated collection of patient-reported outcomes.. <i>Journal of Clinical Oncology</i> , 2012, 30, 56-56.  | 0.8 | 0         |
| 122 | Mutations In UBA3 Confer Resistance To The NEDD8-Activating Enzyme Inhibitor MLN4924 In Human Leukemic Cells. <i>Blood</i> , 2013, 122, 2527-2527.  | 0.6 | 0         |
| 123 | Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia. <i>Blood</i> , 2015, 126, 3803-3803.   | 0.6 | 0         |
| 124 | A Phase 1b Study of Panobinostat in Combination with Idarubicin and Ara-C in Patients with High-Risk Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2553-2553.   | 0.6 | 0         |
| 125 | Optimizing infusion scheduling through lean methods and data science.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18240-e18240.   | 0.8 | 0         |
| 126 | Quality of life of acute myeloid leukemia patients in a real-world setting.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18525-e18525.   | 0.8 | 0         |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 127 | Real-world prescribing patterns in acute myeloid leukemia in the United States.. Journal of Clinical Oncology, 2017, 35, e18524-e18524.  | 0.8 | 0         |
| 128 | Outcomes by number of induction cycles with CPX-351 vs 7+3 chemotherapy in older adults with newly diagnosed, high-risk/secondary acute myeloid leukemia (sAML).. Journal of Clinical Oncology, 2018, 36, 7040-7040. | 0.8 | 0         |
| 129 | Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study. Blood, 2018, 132, 1388-1388.      | 0.6 | 0         |